Copyright (c) 1996-2013 Constant Contact. All rights reserved. Except as permitted under a separate written agreement with Constant Contact, neither the Constant Contact software, nor any content that appears on any Constant Contact site, including but not limited to, web pages, newsletters, or templates may be reproduced, republished, repurposed, or distributed without the prior written permission of Constant Contact. For inquiries regarding reproduction or distribution of any Constant Contact material, please contact legal@constantcontact.com.

Partners in Practice

January, 2013

Welcome to the Partners In Practice
E-Newsletter.

A quarterly, physician publication from the Department of Medicine at Roswell Park, keeping you updated on cancer advances and patient services.

 

Novel Anti-Angiogenic Therapies for Metastatic Colorectal Cancer

Overview of VEGF and VEGF receptors.

The role of VEGF pathway and angiogenesis in metastatic colorectal cancer (mCRC) has evolved, and there has been a keen interest in exploiting this knowledge for therapeutic intervention. In the past few months, two novel anti-angiogenic agents, Ziv-Aflibercept and Regorafenib, have been approved for by the FDA for mCRC.

Read more…

 

Screening for Lung Cancer in High-Risk Patients

X-Ray of Lung Cancer.

Lung cancer is the leading cause of death from cancer. Unfortunately, current diagnostic algorithms are focused on symptomatic individuals leading to diagnosis in advanced stages. The concept of developing an effective screening program is based on the premise that this approach would lead to diagnosis at an earlier stage that can be treated more effectively, resulting in a significant impact on overall morbidity and mortality related to this aggressive disease.

Read about theRPCI High-Risk Lung Cancer Screening Program developed with this aim in mind.

Is your patient eligible for our high-risk program? Complete our online risk assessment form to find out.

 

MEK Inhibitors In Cancer

This is an image with a Doctor and Patient.

Mitogen-activated protein kinases (MAPKs) are serine/threonine kinases involved in various signaling pathways. The best characterized of these, the Ras/Raf/MEK/ERK cascade, impacts a diverse array of downstream molecular outcomes including cell proliferation, differentiation, apoptosis, and angiogenesis. This pathway is an attractive target as it has an established role in a variety of human cancers, particularly those associated with activation of RAS proteins that constitute approximately 20% of human cancers, and BRAF kinase mutations.

A recent study called the METRIC trial evaluated the role of an oral MEK inhibitor, trametinib, in BRAF mutated metastatic melanoma.

Read more…

Contents

Colorectal Cancer
Lung Cancer Screening
MEK Inhibitors

Helpful Links

Clinical Trials at RPCI
CME
Refer a Patient
NCCN Guidelines
Patient Support Groups
Partners In Practice Resources
Physician Directory

New Faces at Roswell Park

Meet some of the new physicians of Roswell Park by visiting this page.

Social Media

Share this

Know someone who might be interested in the email? Why not forward this email to them.

Unsubscribe

Don't want to receive these emails any more. Please unsubscribe instantly.

Copyright (c) 1996-2013 Constant Contact. All rights reserved. Except as permitted under a separate written agreement with Constant Contact, neither the Constant Contact software, nor any content that appears on any Constant Contact site, including but not limited to, web pages, newsletters, or templates may be reproduced, republished, repurposed, or distributed without the prior written permission of Constant Contact. For inquiries regarding reproduction or distribution of any Constant Contact material, please contact legal@constantcontact.com.